These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10225005)

  • 1. T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine.
    Gez E; Mekori T; Struminger L; Rubinov R; Nativ O; Stein A; Haim N; Kuten A
    Cancer Invest; 1999; 17(4):259-63. PubMed ID: 10225005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
    Hernberg M; Muhonen T; Pyrhönen S
    Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.
    Göhring B; Riemann D; Rebmann U; Heynemann H; Schabel J; Langner J
    Urol Res; 1996; 24(5):297-303. PubMed ID: 8931295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
    Atzpodien J; Kirchner H; Duensing S; Lopez Hänninen E; Franzke A; Buer J; Probst M; Anton P; Poliwoda H
    World J Urol; 1995; 13(3):174-7. PubMed ID: 7550391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma.
    Characiejus D; Pasukoniene V; Kazlauskaite N; Valuckas KP; Petraitis T; Mauricas M; Den Otter W
    Anticancer Res; 2002; 22(6B):3679-83. PubMed ID: 12552976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
    J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.
    Herrmann E; Brinkmann OA; Bode ME; Bierer S; Köpke T; Bögemann M; Hertle L; Wülfing C
    Eur Urol; 2007 Jun; 51(6):1625-31; discussion 1631-2. PubMed ID: 17113215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma?
    Merimsky O; Shnider BI; Chaitchik S
    Mol Biother; 1991 Mar; 3(1):34-7. PubMed ID: 2069758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.
    Wersäll P; Mellstedt H
    Med Oncol; 1995 Jun; 12(2):69-77. PubMed ID: 8535664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European studies of interleukin-2 in metastatic renal cell carcinoma.
    Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
    [No Abstract]   [Full Text] [Related]  

  • 16. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
    Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
    Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine.
    Massidda B; Migliari R; Padovani A; Scarpa RM; Pellegrini P; Cortesi E; Usai E; Pellegrini A
    J Chemother; 1991 Dec; 3(6):387-9. PubMed ID: 1819623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.